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Problem: APOBEC3G (A3G) is a cytidine deaminase that exhibits antiviral activity by 
introducing C-to-T hypermutation in viral DNA.  We recently observed the distinct presence 
of C-to-T hypermutation of human papillomavirus DNA in uterine cervical intraepithelial 
neoplasia (CIN), suggesting the possible involvement of A3G in the mutation-inducing 
process.  Consequently, we investigated the association of A3G expression with CIN 	
progression in this study. 

 
Method of Study:  Patients who had undergone cervical conization due to CIN 1 (n=11),  
CIN 2 (n=9), CIN 3 (n=12), and microinvasive squamous cell carcinoma (n=2) were included.    
The expression profiles of A3G and p16 proteins in cervical lesions and A3G-positive  
immune cells around the lesions were examined by immunohistochemistry.    
     
Results: Immunoreactive A3G protein was detected in the CIN and squamous cell carcinoma  
lesions.  Its expression intensity and positive areas were increased and spread in accordance  
with the progression of CIN, respectively.  The co-expression of p16 was observed on the  	
A3G-positive atypical cells.  The numbers of A3G-positive immune cells in CIN 3 lesions  

were significantly higher than those of CIN 1-2 lesions.   
      
Conclusions: These findings indicate that A3G is associated with CIN, suggesting its  
important roles in human papillomavirus-induced pathophysiological processes such as CIN 




 Uterine cervical carcinoma is the second most commonly diagnosed cancer and 
third leading cause of cancer death among females in developing countries. Most cases of 
cervical carcinomas are found in women younger than 50 [1].  Human papillomavirus (HPV) 
plays a central role in the pathogenesis of cervical neoplasia [2].  Although HPV infection in 
the genital tract is common, only a small number of infected women develop cervical cancers, 	
indicating that HPV infection alone is not sufficient to promote cervical neoplasia.  It has 

been widely accepted that persistent HPV infection causes its integration, inactivating tumor 
suppressor genes, pRb and p53, and results in the accumulation of multiple gene mutations in  
cervical cells, leading to the activation of cellular oncogenes.  However, the precise   
mechanisms that induce multiple gene mutations and integration remain unknown.   
 The AID (activation-induced cytidine deaminase) /APOBEC (apolipoprotein B  
mRNA editing enzyme, catalytic polypeptide-like) family is a group of cytidine deaminases,  
which convert cytosine (C) to uracil (U) in DNA/RNA [3].  In humans, the APOBEC family  
is composed of 11 members: AID and APOBEC1, 2, 3A, 3B, 3C, 3D, 3F, 3G, 3H, and 4.   
APOBEC3s are considered to be intrinsic antiviral factors.  Among them, APOBEC3G  	
(A3G) was reported to inhibit the reverse transcription of HIV-1 and HBV in infected cells,  

introducing C-to-T hypermutation in viral DNA [4-5].  Sexual intercourse is one of the main  
routes of HIV and HBV infections.  In addition, high expression of A3G was reported in the 
uterine cervix with intercourse-mediated HPV infection [6-7].  Based on these findings, it  
can be speculated that A3G contributes to innate immune systems in the uterine cervix [8].  
 Recently, APOBEC3 proteins were proposed to be involved in carcinogenesis.  It 
has been reported that APOBEC3s may contribute to the mutation load in multiple human 
tumors, including bladder, lung, head and neck, and breast cancers [9-10].  APOBEC3s are a 
“two-edged blade”: they act as antiviral factors, while their overexpression or persistent 
 
expression might induce carcinogenesis. This has led to the hypothesis that there is a potential  
link between virus restriction and cancer mutagenesis by APOBEC3s [11-12]. 
 We recently reported the possible involvement of APOBEC3s in the process of gene 
mutation in cervical cancer cells by demonstrating the distinct presence of C-to-T 
hypermutation of HPV-DNA in CIN lesions, which can be induced by APOBEC3s including 
A3G [7, 13].  Consequently, in this study, we examined the expression profiles of A3G 
protein in CIN lesions by immunohistochemical staining.  To investigate the stage-specific 	
association of HPV infection, we also examined the expression of p16 protein and analyzed 

the relationship between A3G and p16 protein expressions.    
  
Materials and Methods   
  
Patients  
 Thirty-four patients who had undergone cervical conization due to CIN and/or  
microinvasive squamous cell carcinoma of the cervix were included in this study.  Among  
them, 11 cases were CIN 1, 9 cases were CIN 2, 12 cases were CIN 3, and 2 cases were  
microinvasive carcinomas.  Two cases of cervical invasive carcinoma tissues, squamous cell  	
carcinoma and adenocarcinoma, were also obtained from patient who had undergone radical  

surgery.  Four normal cervical specimens were also obtained from patients who had  
undergone hysterectomy due to uterine myoma and were used for negative control staining.  
All tissue sections from formalin-fixed, paraffin-embedded blocks were prepared at the  
Department of Pathology, Kanazawa University Hospital, and routine pathological diagnosis 
using the hematoxylin and eosin stained sections was reviewed by two pathologists.  The 
sequential tissue sections at the same lesions were used for the following 
immunohistochemical study.  
 This was a retrospective observational study approved by the Medical Ethics 




 Immunohistochemical staining was performed using the standard avidin–biotin 
complex peroxidase method, as described previously [14].  Briefly, non-stained tissue 
sections were deparaffinized and pretreated with Target Retrieval Solution (pH 6, S2031, 
DAKO, Glostrup, Denmark) at 96°C for 30 min.  As pretreatment, endogenous peroxidase 
was blocked with 3% H2O2 for 10 min.  The primary antibodies used in this study were as 	
follows: rabbit anti-A3G (Sigma-Aldrich, HPA001812, Sigma-Aldrich, St Louis, MO, USA) 

and antibody raised against A3G peptide [CQDLSGRLRAILQNQEN] [15], rabbit anti-p16 
(clone DCS-50, 65174, Progen Biotechnik GMBH, Heidelberg, Germany).  Normal rabbit  
IgG was used in place of the primary antibody as a negative control.   
 Primary antibody diluted to an adequate concentration was applied to the tissue  
sections at room temperature for 1 hour in a humid chamber.  After washing three times in  
PBS, the sections were incubated with secondary biotinylated antibody for 30 min at room  
temperature. Antigen–antibody complexes were detected with the avidin–peroxidase method  
using diaminobenzidine as a chromogen substrate (Vectastain ABC-Kit, Vector Laboratories,  
Burlingame, CA, USA) according to the manufacturer’s instructions. The tissues sections  	
were counterstained with hematoxylin and then examined by microscopy.  Two dedicated  

gynecologists reviewed slides and evaluated the immunohistochemical data. A3G expression  
was also assessed by fluorescent immunostaining using a tyramide signal amplification 
system with TSA plus the TMR kit (Perkin Elmer, Waltham, MA, USA) [16].    
 
RT-PCR analysis of APOBEC3G gene expression 
For RT-PCR, we used 2 CIN1, 2 CIN2, 4 CIN3 and, 1 invasive SCC, 1 invasive 
cervical adenocarcinoma samples of 10 cases.  Total RNA was extracted from three 3m 
sections of formalin-fixed, paraffin-embedded tissue using the “NucleoSpin totalRNA FFPE 
XS” Kit (Macherey-Nagel, Düren, Germany).  Extracted RNA of 300ng was 	
 
reverse-transcribed using PrimeScript reverse transcriptase III (TaKaRa) with random primers  
(nonadeoxyribonucleotide mixture; pd(N)9) (Takara bio Inc., Shiga, Japan).  The cDNA was 
amplified using specific primers as follows; A3G forward primer, 
GGGACCCAGATTACCAGGAG (exon 3); A3G reverse primer, 
GCAGATTATTCCAAGGCTCAA (exon 4) [17], hypoxanthine phosphoribosyltransferase 1 
(HPRT1) forward primer, GCCCTGGCGTCGTGATTAGT; HPRT1 reverse primer, 
CGAGCAAGACGTTCAGTCCTGTC [15].  All PCR reactions were performed in a final 	
volume of 20 µl reaction mixture containing PCR Premix Ex Taq (Takara Bio Inc., Shiga, 

Japan), cDNA equivalent to 30ng of total RNA, and 200 nM of each primer.  PCR was 
performed under the following conditions; a single hot-start cycle at 95°C for 30 sec,  
followed by 36 cycles of denaturing at 95°C for 5 sec, annealing and extension at 60°C for 20   
sec.  Amplification was completed by an additional cycle at 95°C for 1 min, and products  
were analyzed by 2% agarose gel electrophoresis and stained with ethidium bromide.  
  
Assessment of the expression profiles of A3G and p16 in CIN lesions  
 All CIN lesions were examined in a magnified area (x100) for quantification.  
Images were captured using an Olympus BX50 microscope and a DP72 Olympus digital  	
camera, and Cellsens standard 1.5 software. (Olympus, Japan).  We selected the area  

showing the most severe CIN lesions in each case, and the epithelia of CIN lesions were  
delineated as regions of interest (ROIs).  The rates of the areas of A3G and/or p16-positive 
lesions per corresponding ROIs were calculated and defined as A3G and/or p16-positive area  
ratios.  The intensity of A3G expression was classified into 4 grades: 0, none: 1, weak 
staining: 2, moderate staining: 3, strong, which were independently assessed by three 
individuals.  
   The differences in A3G and/or p16-positive area rates and the expression 
intensities of A3G among CIN I, II, and III groups were analyzed by the Kruskal-Wallis test, 
followed by the Mann-Whitney test.  The correlation of the ratio of positive areas between 	
 	
A3G and p16 was analyzed by Spearman's rank-correlation coefficient test.  The differences  
in expression intensities between A3G and p16 in each CIN group were analyzed by the 
Mann-Whitney test.   
 
Assessment of A3G-positive immune cells 
 We also assessed the infiltration profiles of A3G-positive lymphocytes around CIN 
lesions. To assess infiltration by A3G-positive lymphocytes, the areas of ROIs were extended 	
to the subepithelial stromal regions and defined as follows: the width of the epithelial area 

that includes the CIN lesion is 500 µm, and the depth of the underlying stromal area is 200 
µm.  We counted the number of A3G-positive lymphocytes and normalized values against  
the area of the ROI (mm2) using Image-J software [18].   
 The differences in the numbers of A3G-positive lymphocytes among CIN I, II, and  




The expression profiles of immunoreactive A3G protein in uterine cervix tissues   	
 In the normal cervical tissues, the expression of A3G on the squamous epithelial  

layer was almost undetectable (Figure 1A).  In contrast, positive expression of A3G was  
observed in the CIN lesions.  In the CIN 1 lesions, A3G expression was detected on the 
atypical epithelial cells in the basal layer (Figure 1B).  On the other hand, in the CIN 3  
lesions, A3G was expressed on the atypical cells throughout the whole layer (Figure 1C).  
A3G expression was also observed in squamous cell carcinoma at the microinvasive lesions 
(Figure 1D). 
 To confirm the expression of A3G more specifically, we further performed 
fluorescent immunostaining using another anti-A3G antibody raised against a different 
antigenic peptide corresponding to amino acid sequences of A3G protein.  The staining 	
 

profiles of A3G were similar to those detected by the initial antibody, enhancing the reliability  
of the expression of A3G protein in CIN lesions (Figure 1F-I).  
 
The relationship between A3G expression profiles by immunohistochemically and reverse 
transcription PCR in cervix lesions 
 We performed RT-PCR to evaluate the relationship between 
immunohistochemically reactive A3G protein and expression of A3G mRNA.  In most of the 	
cases with A3G-positive lesion or strong infiltration of A3G-positive immune cells, RT-PCR 

showed positive expression of A3G mRNA.  In contrast, A3G-negative lesion and weak 
infiltration of A3G-positive immune cells showed no or weak mRNA expression of A3G by  
RT-PCR (Fig. 2A and 2B).    
  
The positive rate and intensity of A3G expression in CIN lesions   
 The ratios of the A3G-positive areas in the CIN 3 lesions were significantly higher  
than those in the CIN 1 and CIN 2 lesions, indicating that A3G-positive lesions spread from  
the basal layer toward the whole layer in accordance with the progression of CIN (Figure 3A).   
Similarly, the staining intensity of A3G in the CIN 3 lesions was significantly higher than  	
those of the CIN 1 and CIN 2 lesions (Figure 3B).  

  
The relationship between p16 and A3G expression profiles in CIN lesions 
 To investigate the possible involvement of HPV infection in A3G expression in the  
CIN lesions, we assessed the relationship between A3G and p16 expressions that were 
up-regulated by HPV infection, affecting the RB-p16 pathway [19-20]. 
 In the CIN 1 lesions with A3G-positive atypical cells in the basal layer, the 
expression of p16 was detected not only in the basal layer, but also in thekoilocytotic cells in 
the middle layer (Figure 4A-C).  In the CIN 2 lesions, the area of p16 expression was 
broader than that of A3G expression, covering the A3G-positive areas (Figures 4D).  In all 	
 
CIN 3 lesions, the expression of p16 was detected in the atypical cells throughout the whole  
layer.  Similarly, these p16-positive areas included the A3G-positive cell areas (Figure 
4F-G).   
 To confirm the relationship between the A3G and p16 expression profiles in CIN 
lesions, we quantitated the ratio of the p16-positive area in each CIN lesion and constructed a 
scatter diagram along with those of A3G (Figure 5A).  Although there was no significant 
correlation between A3G and p16-positive area ratios, this scatter diagram demonstrated that 	
almost all ratios of the p16-positive area were higher than those of A3G-positive areas.  

Consequently, we examined the relationship between A3G and p16-positive ratios in each 
grade of CIN, and confirmed that the ratio of the p16-positive area was significantly higher  
than that of A3G in all CIN grades (Figure 5B).    
   
The relationship between CIN grades and A3G-positive lymphocytes  
 In the CIN lesions, we observed A3G-positive cells, which had a round nucleus and  
narrow rim of cytoplasm, infiltrating the epithelial and subepithelial stromal regions (Figure  
1E).  These A3G-positive cells were positive for CD3, a cell marker of T lymphocytes, in  
accordance with previous reports [21] in ovarian cancer (data not shown).  The numbers of  	
A3G-positive cells infiltrating around CIN 3 lesions were significantly higher than those of  





 By immunohistochemical study, we demonstrated that immunoreactive A3G protein 
was expressed in uterine cervical CIN lesions.  To our knowledge, this is the first report of 
A3G expression in human CIN lesions.  Since this was a retrospective study, we could not 
obtain a series of fresh tissue samples that were adequate for analysis using quantitative 
RT-PCR or Western blotting.  Therefore, to confirm the reliability of the expression profiles 	
  
of A3G protein in CIN lesions, we additionally stained A3G protein using another polyclonal  
anti-A3G antibody, which recognizes a synthetic peptide different from that by the initial 
antibody, and confirmed the same staining profiles between the two antibodies.  In addition, 
using total RNA extracted from formalin-fixed, paraffin-embedded tissues, we performed 
RT-PCR and confirmed positive correlation between immunoreactive staining and mRNA 
expression of A3G, supporting the reliability of the presence of A3G in CIN lesions.  Based 
on the expression profiles, the A3G-positive lesions spread from the basal layer toward the 	
whole layer in accordance with the advancing of CIN grades.  The intensity of A3G 

expression was also increased along with the progressive stages of the lesion.    
It is generally accepted that high-risk HPV infection-induced E7 protein causes the  
upregulation of p16, affecting the RB-p16 pathway [19-20].  Consequently, we compared its   
expression profiles with those of A3G.  Although there was no significant correlation  
between A3G and p16 expression area rates, the positive expression areas of p16 significantly  
exceeded those of A3G in all grades of CIN.  On the basis of the molecular mechanisms of  
p16 expression, we speculate that the sequential events are initially HPV infection, then p16  
expression, and subsequently A3G expression.  These findings also suggest that A3G  
expression is induced by certain mechanisms during continuous infection by HPV.  To  	
support the above speculation, in the low-grade lesions, A3G was expressed only on the  

basal-like atypical cells, not on the cells with koilocytotic changes where p16 was clearly  
expressed (Figure 3B).  The A3G expression was also observed in the microinvasive cancer 
cells in the very early stage, supporting the continuous expression of A3G from CIN to cancer  
cells (Figure 1D).  These findings are compatible with our hypothesis that A3G is related to 
the process of HPV infection-induced malignant alternation, inducing integration of viral 
DNA in the infected cervical epithelial cells [22-23].  A3G expression increases upon CIN 
progression.  It would be interesting to investigate relationship between A3G expression 
level, viral copy number and integration status, though technically not easy.  Information of 
A3G expression and viral gene in the cellular level may give us a hint to answer why A3G 	
   
expression increases with CIN progression.  On the other hand, it should be also noted that  
there were certain cases showing low expression of A3G in CIN3.  Although we could not 
provide information about the type of HPV infection in this study, it is possible that the 
expression profiles of A3G are influenced by HPV type.  Further prospective studies to 
assess relativity between HPV type and A3G expression should be required in the future. 
 The mechanism of inducing A3G expression in the CIN lesions remains unknown. 
In this study, we observed that a large number of A3G-positive immune cells had infiltrated 	
around the CIN lesions.  Based on our preliminary study using a double-fluorescence 

staining method, these cells also expressed CD3, as was reported in the case of ovarian 
cancers [21].  Importantly, the number of the A3G-positive T cells increased according to the  
grade of the CIN lesions, suggesting that these immune cells are involved in the pathological   
course of HPV-induced CIN lesions.  It is generally accepted that T cells enhance A3G  
expression, responding to viral infections such as HIV [24-25].  Among cytokines, IFNs  
were reported to enhance A3G expression in T cells, acting as not only an intrinsic antiviral  
factor but also an inducer of the adaptive immune system [23, 26-27].  Considering both  
anti-virus effects of A3G and a characteristic distribution of A3G-positive T cells, it can be  
speculated that A3G-positive T cells that have infiltrated around CIN lesions respond to the  	
viral infection or the cytotoxic activation of local immune networks against viral infection.   

On the other hand, upregulation of A3G expression in infiltrated T cells was also reported in  
non-virus related cancers [21].  Since high A3G expression was correlated with improved 
outcomes in multiple HGSOC cohorts [21], A3G-positive T cells may play a role in  
eliminating transformed cells in CIN lesions.   
 We previously demonstrated that IFNs could also induce A3G expression on 
HPV-infected human squamous cell-derived cell lines, W12 cells, and VU147T in vitro 
[22-23].  This suggests that IFNs can induce A3G expression on the uterine cervical 
squamous cells.  Although we failed to detect the specific expression of IFN-g in these 
immune cells using our tools of immunohistochemistry (data not shown), it is reasonable to 	
  
consider the A3G-positive T cell as a candidate to induce A3G expression on HPV-infected  
squamous cells in CIN lesions.  It should also be noted that we cannot deny the possibility 
that the intracellular molecular cascades induced by HPV infection elicit A3G production 
within their own cell bodies.              
 In our previous study, we reported that A3G expression induced by IFN-b leads to 
E2 hypermutation in W12 cells in vitro [23].  We further showed that C-to-T hypermutation 
of HPV genome was present in HPV-positive CIN lesions in vivo using next-generation 	
sequencing and differential denaturation DNA-PCR.  Mutation pattern of the hypermutated 

E2 gene in these studies suggest the involvement of A3A, 3B, 3C and 3G as responsible 
APOBEC proteins [7,13].  This disrupted E2 protein function caused by mutation then leads  
to alleviation of the E2-mediated repression and enhances expression of the E6 and E7 genes   
[28].  Although there is no additional evidence that allows us to go beyond the previously  
proposed mechanisms, this study is consistent with the possibility that among APOBEC3s,  
A3G is involved in the above mechanisms to induce malignant progression in CIN.  Since  
the expression profiles are specific to the developmental stages in CIN lesions, A3G may  
become one of the useful biomarkers to assess CIN progression.  
 In conclusion, we immunohistochemically demonstrated that A3G protein was  	
expressed in the uterine cervical CIN lesions.  A3G expression was enhanced along with the  

progressive stages of CIN lesions.  These findings suggest that A3G expression is induced in  
CIN lesions during continuous HPV infection, and support our previous hypothesis that 
APOBEC3s are involved in the process of HPV infection-induced malignant alternation,  
inducing gene mutation in cervical cancer cells.  Interestingly, a number of A3G-positive T 
cells infiltrated around the CIN lesions.  Although no definitive evidence was provided in 
this study, the A3G-positive T cell is a candidate to induce A3G expression on HPV-infected 
squamous cells in CIN lesions. Further investigation of the pathological roles of APOBEC3s 
including A3G in CIN lesions will contribute to clarifying the precise mechanisms of the 
carcinogenetic progression of HPV-infected cervical lesions and developing new therapies to 	
  
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Figure legends  
 
Figure 1.  The expression profiles of immunoreactive A3G protein in uterine cervix tissues 
 A-E, immunohistochemical staining of A3G in normal uterine cervical epithelium 
(A), CIN 1 (B), CIN 3 (C), and microinvasive squamous cell carcinoma (D and E).  A, the 
expression of A3G on the squamous epithelial layer was undetectable.  B, A3G expression 
was moderately detected on the atypical epithelial cells in the basal layer.  C, A3G was 	
strongly expressed on the atypical cells throughout the whole layers in the CIN 3 lesions. D, 

the expression of A3G was moderately observed in squamous cell carcinoma at the 
microinvasive lesions.  E, a magnified image of the black box area in D.  C and E,  
A3G-positive infiltrating cells (arrows) were observed in the epithelial region of CIN 3 (C)   
and in the underlying stromal regions of CIN 3 and microinvasive carcinoma lesions (C and  
E).  Bars show 100 µm.  F-H, double fluorescent immunostaining of a CIN 2 lesion.  F,  
A3G (red) staining using a different antibody.  G, nuclear staining (blue) using DAPI.  H, a  
merged image of F and G.  A3G (red) was expressed in the basal layer (white arrows, H).  I,  
immunohistochemical staining of A3G in the corresponding sequential tissue section using  
the same antibody in F and the DAB system.  Bars show 50 µm.  	
  

Figure 2. The relationship between A3G expression profiles by immunohistochemically and  
reverse transcription PCR in uterine cervical lesions 
 A, immunohistochemical staining of A3G in CIN lesions, uterine cervical invasive  
SCC, and invasive adenocarcinoma. Bars show 100 µm. 
 B, RT-PCR analysis of A3G and HPRT1 mRNA expression in each uterine cervical 
lesion. The data shown are representative of two independent experiments. Product sizes are 
shown in base pairs. M: Molecular weight marker (25bp). 
 
Figure 3. The positive ratio and intensity of A3G expression in CIN lesions 	
  
 A, the positive ratios of A3G expression areas in CIN 1, 2, and 3 lesions.  The  
ratios of the A3G-positive area in CIN 3 lesions were significantly higher than those in CIN 1 
and CIN 2 lesions.  On the other hand, there was no significant difference in A3G-positive 
areas between CIN 1 and CIN 2.  *P< 0.05; ** P<0.01.  B, the intensity of A3G expression 
in CIN lesions.  The expression intensities of A3G in CIN 3 lesions were significantly higher 
than those in CIN 1 and CIN 3 lesions.  *P< 0.05; ** P<0.01. 
 	
Figure 4.  The expression profiles of p16 protein in CIN lesions 

 A-C, a lesion of CIN 1; D and E, CIN 2; F and G, CIN 3.  A, D, and F, A3G 
staining; B, C, E, and H, p16 staining.  A-C, in CIN 1 lesions showing A3G-positive atypical  
cells in the basal layer (A), the expression of p16 was detected not only in the basal layer, but   
also in the koliocytotic cells in the middle layer (B and C, arrows). C, a magnified image of  
the black box area in B.  D and E, the area of p16 expression was broader than that of A3G  
expression, covering the A3G-positive areas.  F and G, the expressions of both A3G (F) and  
p16 (G) were detected in the atypical cells throughout the whole layer in all CIN 3 lesions.   
Bars show 100 µm.  
  	
Figure 5. The relationship between p16 and A3G expression in CIN lesions  

 A, a scatter diagram showing the ratios of both A3G-positive and p16-positive areas.   
To confirm the relationship between the A3G and p16 expression profiles in CIN lesions, we 
quantitated the ratio of the p16-positive area in each CIN lesion and constructed a scatter  
diagram along with those of A3G.  Although there was no significant correlation between 
A3G- and p16-positive area ratios, the scatter diagram demonstrated that almost all ratios of 
p16-positive areas were higher than those of A3G-positive areas.  B, a comparison of the 
paired ratios of A3G-positive and p16-positive areas in each grade of CIN.  The p16-positive 
area was significantly larger than that of A3G in all CIN grades. *P< 0.05; ** P<0.01. 
 	
 
Figure 6.  The relationship between CIN grades and A3G-positive lymphocytes  
 The numbers of A3G-positive cells infiltrating around CIN 3 lesions were 
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